NCT06952296尚未招募不适用
Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Abbott
- 入组人数
- 250
- 主要终点
- Changes in visual analogue scale (VAS) score of dysmenorrhea, Chronic Pelvic Pain (CPP), dyspareunia, and other Endometriosis related Pain (ERP) after dydrogesterone treatment from baseline to Cycle 6.
研究概览
简要总结
The study is an observational, multicenter, prospective, single arm study to evaluate the efficacy of dydrogesterone in endometriosis-related pain (EAP).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, ≥18 and ≤45 years of age.
- •With normal menstrual cycles (according to the International Federation of Gynecology and Obstetrics [FIGO]-2018 classification system) in the preceding 6 months before Cycle 0, defined as menstrual frequency ≥24 to ≤38 days, menstrual duration ≤8 days, shortest to longest cycle variation ≤7-9 days, normal flow volume (patient determined) and no intermenstrual bleeding.
- •Have clinically or surgically diagnosed endometriosis according to routine clinical practice.
- •Complaints of ERP.
- •Prescribed treatment with Duphaston® according to the local approved label for treatment of endometriosis 10 mg BID or TID from the 5th to the 25th day of the menstrual period.
- •Signed informed consent form (ICF).
排除标准
- •With definite diagnosis of adenomyosis confirmed by clinical diagnosis or histopathology.
- •Routine consumption of analgesics other than for the pain of endometriosis.
- •Patients receiving hormonal treatment (e.g., dienogest, levonorgestrel releasing intrauterine system, dydrogesterone, etc.) or hormonal contraceptives (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives, etc.) during the previous menstrual cycle prior to Cycle
- •Ongoing pregnancy.
- •Menopause or premature ovarian failure.
- •Had surgery within 3 months before enrollment or have planned surgery during the study.
- •Any coexisting disease(s) with or without chronic concomitant medication that may affect the assessment of pain intensity at the investigator's judgment.
- •With any metabolic and genetic diseases that may affect pregnancy and fetus at the investigator's judgment.
- •With contraindications for dydrogesterone treatment listed in the locally approved label (instructions for the medical use of Duphaston®).
- •Other conditions that made the patient's participation impossible (based on the investigator's decision).
- •Fertility treatments requiring assisted reproductive technology.
- •Patients simultaneous participating in any interventional clinical study during observation period.
研究组 & 干预措施
Dydrogesterone group
干预措施: Dydrogesterone (Drug)
结局指标
主要结局
Changes in visual analogue scale (VAS) score of dysmenorrhea, Chronic Pelvic Pain (CPP), dyspareunia, and other Endometriosis related Pain (ERP) after dydrogesterone treatment from baseline to Cycle 6.
时间窗: From baseline to Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average)
The VAS consists of a 100-mm line with the end points no pain and worst pain, which "absence of pain" corresponds to the value of "0" and unbearable pain corresponding to the value of "100" . Patients will be asked to point the average pain intensity throughout the last menstrual cycle.
次要结局
- Changes in menstrual cycle duration from baseline to Cycle 3 and Cycle 6.(From baseline to Cycle 3 and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- Changes in visual analogue scale (VAS) score of dysmenorrhea, Chronic Pelvic Pain(CPP), dyspareunia, and other Endometriosis related Pain (ERP) after dydrogesterone treatment from baseline to Cycle 3.(From baseline to Cycle 3 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- Changes in Endometriosis Health Profile Questionnaire-30 (EHP-30) after dydrogesterone treatment from baseline to Cycle 3 and Cycle 6.(From baseline to Cycle 3 and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- Changes in score of pain domain of Endometriosis Health Profile Questionnaire (EHP-30) from baseline to Cycle 3 and Cycle 6.(From baseline to Cycle 3 and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- Changes in sexual well-being after dydrogesterone treatment by 5-points Likert scale from baseline to Cycle 3 and Cycle 6.(From baseline to Cycle 3 and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- The number of days per menstrual cycle when analgesics are taken at baseline, Cycle 3, and Cycle 6.(At baseline, Cycle 3, and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- The proportion of participants with amenorrhea, infrequent bleeding, frequent bleeding, irregular bleeding, prolonged bleeding upon treatment with dydrogesterone at baseline, Cycle 3, and Cycle 6.(At baseline, Cycle 3, and Cycle 6 ("Cycle" refers to menstrual cycle, 1 cycle is 28 days on average))
- The absolute number and percentage of adverse drug reactions (ADRs) / other pharmacovigilance-relevant information (OPRI) reported with dydrogesterone treatment.(Time Frame: From informed consent to last contact (refers to cycle 6 visit, where "Cycle" refers to menstrual cycle, 1 cycle is 28 days on average) or 5 half-lives (75 hours from the last dose), whichever is longer.)
研究者
相似试验
已完成
4 期
Dydrogesterone in the Treatment of Endometrial PolypsEndometrial PolypNCT03790215Peking Union Medical College Hospital60
已完成
3 期
Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened MiscarriagePregnancyNCT02128685The University of Hong Kong406
招募中
3 期
Comparison the use of dyrogesterone and steroid in IVF Cycles.Female infertility.Female infertilityIRCT20181031041519N2Tehran University of Medical Sciences200
招募中
不适用
Checking the effect of oral Dydrogesterone (Duphaston) on preventing preterm laborIRCT20190107042266N1Semnan University of Medical Sciences100
已完成
2 期
Evaluation of the effect of oral Dydrogesterone (Duphaston) in threatened abortion at first trimesterThreatened abortionThreatened abortion.IRCT20120918010876N5Shahid Beheshti University of Medical Sciences170